Free Trial
OTCMKTS:GNGBY

Getinge AB (publ) (GNGBY) Stock Price, News & Analysis

Getinge AB (publ) logo
$15.83 +0.14 (+0.89%)
(As of 12/20/2024 05:55 PM ET)

About Getinge AB (publ) Stock (OTCMKTS:GNGBY)

Key Stats

Today's Range
$15.59
$15.83
50-Day Range
$14.91
$20.03
52-Week Range
$14.84
$22.85
Volume
75,181 shs
Average Volume
19,020 shs
Market Capitalization
$4.31 billion
P/E Ratio
26.83
Dividend Yield
1.45%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, mechanical circulatory support, advanced patient monitoring, ICU infrastructure equipment, patient flow management, and drainage solutions. The company also provides surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation, and drainage solutions; and operating room infrastructure equipment, anesthesia, advanced patient monitoring, operating room management, and operating room integration solutions. In addition, it offers pre-cleaning, cleaning and disinfection, sterilization, consumables, endoscope reprocessing, and sterile supply management solutions; connected medical devices; bioreactor systems, DPTE systems, Getinge isolators, terminal sterilization products, and sterilizers; and vivarium, biohazardous materials handling solutions, labware cleaning and sterilization, upstream bioprocessing, and bioreactor preparation solutions. It offers its products through a network of sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia and Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.

Receive GNGBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Getinge AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

GNGBY Stock News Headlines

Getinge price target lowered to SEK 180 from SEK 190 at JPMorgan
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Kepler Capital Reaffirms Their Hold Rating on Getinge (0GZV)
Getinge (0GZV) Receives a Hold from Kepler Capital
See More Headlines

GNGBY Stock Analysis - Frequently Asked Questions

Getinge AB (publ)'s stock was trading at $22.2340 on January 1st, 2024. Since then, GNGBY stock has decreased by 28.8% and is now trading at $15.83.
View the best growth stocks for 2024 here
.

Getinge AB (publ) (OTCMKTS:GNGBY) issued its earnings results on Friday, October, 18th. The company reported $0.21 EPS for the quarter. The business earned $755.49 million during the quarter. Getinge AB (publ) had a net margin of 5.04% and a trailing twelve-month return on equity of 8.27%.

Shares of GNGBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Last Earnings
10/18/2024
Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
OTCMKTS:GNGBY
CIK
N/A
Employees
11,386
Year Founded
N/A

Profitability

Net Income
$227.45 million
Pretax Margin
7.07%

Debt

Sales & Book Value

Annual Sales
$3.00 billion
Cash Flow
$1.62 per share
Book Value
$10.53 per share

Miscellaneous

Free Float
N/A
Market Cap
$4.31 billion
Optionable
Not Optionable
Beta
0.79

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (OTCMKTS:GNGBY) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners